Tata Asset Management (4.1%) and Motilal Oswal AMC (2.8%) are among the other prominent domestic fund holders in HCG. Foreign portfolio investors, meanwhile, collectively own 2.2% of the company.
Also Read: Kotak Mahindra Bank block deal: Sumitomo Mitsui to sell 1.65% stake in lender for ₹6,166 crore
The latest stake sale comes nine months after CVC Capital exited its controlling position in HCG, selling a majority stake to KKR at ₹445 per share. Until March 2025, Aceso was classified as a promoter with a 60.4% holding in the cancer-care hospital chain, but by June-end its stake had fallen to 8.8%.Shares of HCG, which touched a record high earlier this month, closed Wednesday at ₹695.05 on NSE, up 1% for the day. The stock has rallied 42% year-to-date, far outpacing the 3% gain in the broader NSE 500 index.
Despite a weaker performance in FY25 — with net profit down 8% to ₹44 crore on revenues of ₹2,223 crore (up 16.5% YoY) — analysts remain upbeat. Seven of the eight analysts tracking the stock on Bloomberg rate it a “Buy”, with Ambit Capital assigning the highest 12-month target of ₹860.
Also Read: Voltamp Transformers block deal: Promoter may sell 7% stake for $67 mn
HealthCare Global Enterprises operates cancer treatment clinics, multispecialty hospitals, and fertility treatment centres, while Aceso Company remains part of the CVC Network.
